DICE Therapeutics
Lisa Hubbs has over 20 years of work experience in various financial and accounting roles. Lisa is currently employed as the Senior Director of SEC Reporting & Technical Accounting at DICE Therapeutics since April 2022. Prior to this, they worked at Adamas Pharmaceuticals, Inc., where they held the positions of Director of SEC Reporting from August 2016 to March 2022, and Senior Manager of SEC Reporting from June 2015 to August 2016.
Before joining Adamas Pharmaceuticals, Inc., Lisa worked at Crown Castle as the Senior Manager of Property Management Operations from October 2012 to June 2015. Lisa also had a role at NextG Networks, which was acquired by Crown Castle, where they served as the Corporate Controller from March 2010 to October 2012 and as the Assistant Controller from October 2009 to March 2010.
Lisa's work experience also includes a position as a Consultant at NextG Networks from August 2008 to October 2009, as well as an Internal Audit Manager at VeriSign, Inc. from June 2005 to August 2008. Lisa started their career as an Accounting Manager at Instill Corp. from April 2004 to June 2005 and worked as a Senior Auditor at Deloitte & Touche from September 2000 to April 2004.
Lisa Hubbs attended Utah State University from 1994 to 1998, where they earned their Bachelor of Science degree in Accounting. Lisa then pursued further education at the same university from 1999 to 2000, obtaining a Masters degree in Accounting. Additionally, Lisa has achieved certifications as a Certified Internal Auditor (CIA) and a Certified Public Accountant (CPA), both awarded by the State of California, although the specific dates of obtaining these certifications are not provided.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.